Literature DB >> 19923474

What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?

Igor M Belyakov1, Jeffrey D Ahlers.   

Abstract

The route of vaccination is important in influencing immune responses at the initial site of pathogen invasion where protection is most effective. Immune responses required for mucosal protection can differ vastly depending on the individual pathogen. For some mucosal pathogens, including acute self-limiting infections, high-titer neutralizing Abs that enter tissue parenchyma or transude into the mucosal lumen are sufficient for clearing cell-free virus. However, for pathogens causing chronic infections such as HIV, hepatitis C virus, herpes viruses, mycobacteria, and fungal and parasitic infections, a single arm of the immune response generated by systemic vaccination may be insufficient for protection. Induction of the mucosal innate and adaptive immune systems, including CD4+ T help, Th17, high avidity CD8+ CTL, and secretory IgA and IgG1 neutralizing Abs, at the site of pathogen entry may be required for effective protection against highly invasive pathogens that lead to chronic infection and may be generated predominantly by mucosal vaccination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19923474     DOI: 10.4049/jimmunol.0901466

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  106 in total

1.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Authors:  M Jeyanathan; N Thanthrige-Don; S Afkhami; R Lai; D Damjanovic; A Zganiacz; X Feng; X-D Yao; K L Rosenthal; M Fe Medina; J Gauldie; H C Ertl; Z Xing
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

2.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines.

Authors:  Sarah M Baker; James B McLachlan; Lisa A Morici
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

3.  Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex.

Authors:  Bikash Sahay; Natacha Colliou; Mojgan Zadeh; Yong Ge; Minghao Gong; Jennifer L Owen; Melissa Valletti; Christian Jobin; Mansour Mohamadzadeh
Journal:  Vaccine       Date:  2017-11-24       Impact factor: 3.641

Review 4.  Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects.

Authors:  Wasin Charerntantanakul
Journal:  World J Virol       Date:  2012-02-12

5.  Evaluation of virus-specific cellular immune response in transplant patients.

Authors:  Cristina Costa; Alda Saldan; Rossana Cavallo
Journal:  World J Virol       Date:  2012-12-12

Review 6.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

Review 7.  Memories that last forever: strategies for optimizing vaccine T-cell memory.

Authors:  Jeffrey D Ahlers; Igor M Belyakov
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

8.  Evaluation of the Immunogenicity and Protective Efficacy of an Enterotoxigenic Escherichia coli CFA/I Adhesin-Heat-Labile Toxin Chimera.

Authors:  Aisling O'Dowd; Milton Maciel; Steven T Poole; Michael G Jobling; Julianne E Rollenhagen; Colleen M Woods; Stephanie A Sincock; Annette L McVeigh; Michael J Gregory; Ryan C Maves; Michael G Prouty; Randall K Holmes; Stephen J Savarino
Journal:  Infect Immun       Date:  2020-10-19       Impact factor: 3.441

9.  Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model.

Authors:  Brent Sorenson; Kaysie Banton; Lance Augustin; Sean Barnett; Karen McCulloch; Joshua Dorn; Natalie Frykman; Arnold Leonard; Daniel Saltzman
Journal:  Biologics       Date:  2010-03-24

10.  Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses.

Authors:  Graeme E Price; Mark R Soboleski; Chia-Yun Lo; Julia A Misplon; Mary R Quirion; Katherine V Houser; Melissa B Pearce; Claudia Pappas; Terrence M Tumpey; Suzanne L Epstein
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.